Table 1.
Major commercialized and development phase of marine-based anti-cancer compounds/drugs.
| Natural Compounds/Drugs | Source | Company Launched | Status after 2015 Food and Drug Administration (FDA)/European Medicines Evaluation Agency (EMEA) |
|---|---|---|---|
| Brentuximab vedotin 63 (Adcetris™) | Cyanobacteria: Symploca hydnoides and Lyngbya majuscula | Seattle Genetics (Bothell, WA, USA) | In market with antibody-drug conjugates |
| Glembatumumab vedotin | Cyanobacterium: Lyngbya sp. | Celldex Therapeutics | Phase II |
| DMMC (Cyclic depsipeptide) | Cyanobacterium: Lyngbya majuscula | - | Preclinical |
| Largazole | Cyanobacterium: Symploca sp. | - | Preclinical |
| Apratoxin A | Cyanobacterium: Lyngbya boulloni | - | Preclinical |
| Cryptophycin 1 | Cyanobacterium: Nostoc sp. GSV 224 | Merck Pvt. | In market |
| Tasipeptins A–B | Cyanobacterium: Symploca sp. | - | Preclinical |
| Coibamide A | Cyanobacterium: Leptolyngbya sp. | - | Preclinical |